GENFLEET-B (02595) will present preclinical research data on three RAS pathway-related large and small molecule targeted drugs at the 2026 AACR Annual Meeting.

GENFLEET-B (02595) announces that the company will present preclinical research data on three products at the 2026 AACR Annual Meeting poster session. The products include GFH276 (non-degradable molecular glue), GFS784 (novel conjugate drugs linking functional antibodies and mechanism synergistic targeted drug payloads), and GFH603 (covalent modulator for molecular glue activation). The company's RAS therapy matrix focuses on a variety of selective and pan-RAS inhibitors, and continues to explore potential targets of important co-mutations in the RAS pathway. This matrix includes a diverse range of molecules and mechanisms related to the RAS pathway, targeting both large and small molecules. The AACR Annual Meeting will be held from April 17th to 22nd, 2026 in San Diego, USA, and the company's poster presentations will be on April 19th and April 21st respectively.